Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman

Core Viewpoint - Telo Genomics Corp. has appointed John Farlinger as CEO and chairman, succeeding founder Dr. Sabine Mai, who will remain as a director. The company is focused on advancing its telomere-based diagnostic technology and aims to report clinical study results by summer 2026, alongside pursuing FDA application and Medicare reimbursement approval by 2027 [1][2][3]. Management Changes - John Farlinger has been appointed as CEO and chairman, bringing over 30 years of experience in operations, technology, and finance [1][3]. - Dr. Sabine Mai, the founder, will continue to serve as a director after stepping down as CEO [2]. Strategic Goals - Telo Genomics plans to report clinical study results by summer 2026, testing its technology against market leaders [3]. - The company is preparing to file a significant application with the U.S. FDA and aims for Medicare reimbursement approval in 2027 [3]. Financial and Investor Relations - The company has engaged Sheridan Adams, LLC for investor relations services, effective March 1, 2026, with a monthly fee of $4,000 USD for an initial term of six months [5][6]. - Sheridan has been granted 250,000 stock options at an exercise price of $0.05 per share, vesting 36 months after the grant [7]. Director Resignation - Guido Baechler has resigned as Executive Chairman and director, effective March 31, 2026, but will remain as an advisor to the company [8]. Company Overview - Telo Genomics is a biotech company specializing in telomere-based diagnostic solutions, including liquid biopsies for oncology and neurological diseases. The company has over 160 peer-reviewed publications and 30 clinical studies involving more than 3,000 patients [9].